Trazodone Dosage Guide: Safe Prescribing for Depression & Insomnia

Why Accurate Trazodone Dosage Matters for Depression and Insomnia

Trazodone requires a clear balance between efficacy and safety because dosing differs for depression versus insomnia. Standard antidepressant dosing typically starts at 150 mg per day, divided, with a therapeutic range of 150–300 mg/day; higher doses are uncommon and reserved for resistant cases (StatPearls). For depression, the FDA immediate‑release prescribing information recommends initiating at 150 mg/day in divided doses and increasing by 50 mg/day every 3–4 days as tolerated; in older or frail patients clinicians may use lower initial divided doses with slower titration. In inpatient settings, total daily doses up to 600 mg/day are sometimes used per the label. For insomnia, clinicians commonly use 25–100 mg at bedtime, a lower, often off‑label strategy supported in practice (GoodRx). Keep the maximum daily dose ceiling in mind; doses above recommended limits raise risks of arrhythmia and serotonin syndrome (Mayo Clinic).

Before choosing a dose, confirm these baseline checks:

• Indication and severity of depression or insomnia, and expected treatment goal
• Age and fall risk, especially in older adults
• Renal and hepatic function that may alter metabolism
• Concomitant serotonergic or QT‑prolonging medications
• Current orthostatic symptoms or sedation history

Evidence‑linked dosing reduces guesswork at the bedside. Rounds AI helps clinicians find synthesized, citable guidance from guidelines, trials, and labels when time is limited. Rounds AI's evidence‑linked approach enables quick verification of dosing ranges and safety considerations during decision making.

Step‑by‑Step Guide to Prescribing Trazodone Safely

Start with a brief framing that explains why a concise, evidence-linked workflow matters at the point of care. Trazodone prescribing blends antidepressant dosing principles with sedative effects. A structured seven-step process helps you match indication, dose, monitoring, and safety checks to each patient quickly and defensibly.

1. Step 1: Confirm the clinical indication (depression vs. insomnia) and assess baseline severity.

Assess whether trazodone is being used primarily for depressive disorder, insomnia, or adjunctive sleep in depression. Indication guides target dose ranges and urgency of titration; antidepressant regimens often require higher daily doses than sleep-only use (StatPearls – Trazodone). Document baseline symptom severity, functional impact, and prior trials of therapy. Note concomitant serotonergic agents and prior tolerability to sedating antidepressants.

1. Step 2: Review patient age, renal function, and hepatic function to decide if dose adjustment is needed.

Older adults: for insomnia (off‑label), consider 12.5–25 mg qHS; for depression, start lower than standard (e.g., 25–50 mg BID) and titrate cautiously, monitoring orthostatic blood pressure. Encourage verification of geriatric dosing and safety reviews via Rounds AI, which can surface label language and geriatric safety literature. Assess hepatic/renal function as clinically indicated; use caution and slower titration if impairment is present (Mayo Clinic – Trazodone Oral Route). Common pitfall: treating elderly or organ-impaired patients like younger adults. Slower titration reduces falls and daytime somnolence.

1. Step 3: Choose the starting dose based on indication 50mg nightly for insomnia, 150mg daily divided for depression.

For insomnia, a single nighttime dose of around 50 mg is commonly used to leverage sedative effects while minimizing daytime sedation (StatPearls – Trazodone; GoodRx – Trazodone Dosage Guide). For depression, initiate with divided dosing to reach therapeutic antidepressant ranges, often titrating toward 150–300 mg/day as tolerated; some regimens reach 400 mg/day in outpatients, and severe inpatient cases may go higher under specialist supervision (StatPearls – Trazodone; Drugs.com – Trazodone Prescribing Information). Note: dosing differs from other sedating antidepressants; compare ranges when switching agents to avoid inadvertent under- or overdosing.

1. Step 4: Use an evidence-linked tool (e.g., Rounds AI) to retrieve guideline-based citations for the chosen dose.

Use Rounds AI to retrieve FDA labeling and guideline citations for depression dosing, and high‑quality reviews/trials for insomnia, including any guideline cautions (e.g., AASM). Before finalizing the regimen, pull the primary guideline and label references that support your dosing decision. Clinicians using Rounds AI can retrieve guideline-based citations quickly, so they can verify titration steps, confirm interactions and contraindications, and check safety data and monitoring needs at the point of care. Cross-check prescribing information, trials, and safety reviews such as the 2023 clinical safety review to confirm monitoring needs (MDPI – Clinical Review of Trazodone Safety 2023).

1. Step 5: Counsel the patient on titration schedule and potential side-effects.

Explain the anticipated titration plan and expected timelines for benefit, especially when treating depression where response may take weeks. Highlight common adverse effects: sedation, dizziness, orthostatic hypotension, priapism (rare), and possible next-day somnolence (StatPearls – Trazodone; MDPI – Clinical Review of Trazodone Safety 2023). Advise when to seek urgent care for severe adverse events. For insomnia use, recommend taking the dose at bedtime and avoiding driving or operating heavy machinery if sedated the next morning (Rupa Health – Trazodone for Sleep Safety Guidelines).

1. Step 6: Document the prescription and set a follow-up interval for efficacy and safety monitoring.

Record indication, starting dose, titration plan, and specific monitoring parameters in the chart. Set a near-term follow-up (for example, 1–2 weeks) to assess sedation, orthostatic vital signs, and adherence. Monitor blood pressure for orthostatic changes, particularly during dose increases; incidence of orthostatic hypotension rises with higher doses (StatPearls – Trazodone). Include a plan for hepatic function checks if baseline abnormalities exist (Mayo Clinic – Trazodone Oral Route).

1. Step 7: Re-evaluate response; adjust dose or switch therapy using the same evidence-based workflow.

At follow-up, score symptom response and tolerability. Efficacy for depression is typically seen within 150–300 mg/day; response and remission rates vary—verify with FDA labeling and primary trials using Rounds AI (Drugs.com – Trazodone Prescribing Information; StatPearls – Trazodone; MDPI – Clinical Review of Trazodone Safety 2023). If inadequate response or intolerable side effects occur, re-check interactions and drug label warnings, then consider switching or augmentation using the same evidence-linked verification process. Maintain clear documentation of rationale and safety checks (Drugs.com – Trazodone Prescribing Information).

• Over-titration or starting at higher-than-recommended doses in elderly patients — start lower (for insomnia, 12.5–25 mg qHS; for depression, 25–50 mg BID) and titrate slowly (StatPearls – Trazodone; MDPI – Clinical Review of Trazodone Safety 2023).

• Ignoring renal or hepatic impairment — assess hepatic/renal function as clinically indicated; use caution and slower titration if impairment is present (Mayo Clinic – Trazodone Oral Route).

• Inadequate counseling on sedation and orthostatic hypotension — provide clear bedtime dosing advice and fall-precaution instructions to reduce next-day risks (StatPearls – Trazodone; MDPI – Clinical Review of Trazodone Safety 2023).

Closing notes: Use this seven-step workflow as a repeatable template for safe trazodone prescribing. Keep monitoring plans explicit, document decision points, and verify dosing against primary sources. Solutions like Rounds AI's evidence-linked approach can help teams retrieve guideline, trial, and label citations rapidly when confirming doses or managing complex interactions. Clinician leaders evaluating system-level adoption can explore how Rounds AI enables faster, verifiable point-of-care references while preserving clinical judgment. Learn more about Rounds AI's strategic approach to evidence-linked clinical Q&A as you refine medication safety workflows.

Quick Reference Checklist & Next Steps for Trazodone Dosing

This quick checklist condenses key prescribing steps for trazodone into a single, actionable workflow for clinicians. Dosing and titration recommendations align with current clinical reviews and prescribing references (StatPearls; Mayo Clinic). Safety monitoring guidance reflects recent safety reviews (MDPI).

• Verify indication and severity
• Assess age, renal & hepatic function
• Choose starting dose per indication
• Document dose and monitoring plan
• Re‑evaluate after 1‑2 weeks

Always verify doses against primary guidance and labeling (StatPearls; Mayo Clinic). Monitor blood pressure, mood response, and for serotonin syndrome or rare adverse events as noted in safety reviews (MDPI).

Rounds AI helps clinicians access cited answers at the point of care, and teams using Rounds AI can streamline verification during rounds and handoffs. Learn more about Rounds AI's approach to evidence-linked clinical answers and how it supports governance and BAA pathways for enterprise evaluation.